TW200833321A - Pharmaceutical composition for treating hypertension, diabetes mellitus and cardiovascular diseases - Google Patents

Pharmaceutical composition for treating hypertension, diabetes mellitus and cardiovascular diseases

Info

Publication number: TW200833321A
Authority: TW; Taiwan
Prior art keywords: diabetes mellitus; cardiovascular diseases; treating hypertension; pharmaceutical composition; pharmaceutically acceptable
Prior art date: 2000-08-22

Application number

TW097116517A

Other languages

English (en)

Inventor

Malcolm Allison

Marjorie Regan Gatlin

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-22

Filing date

2001-08-20

Publication date

2008-08-16

2001-08-20 Application filed by Novartis Ag filed Critical Novartis Ag

2008-08-16 Publication of TW200833321A publication Critical patent/TW200833321A/zh

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Hematology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Vascular Medicine (AREA)
Gynecology & Obstetrics (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyrrole Compounds (AREA)

TW097116517A 2000-08-22 2001-08-20 Pharmaceutical composition for treating hypertension, diabetes mellitus and cardiovascular diseases TW200833321A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US64364200A	2000-08-22	2000-08-22

Publications (1)

Publication Number	Publication Date
TW200833321A true TW200833321A (en)	2008-08-16

Family

ID=24581693

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW097116517A TW200833321A (en)	2000-08-22	2001-08-20	Pharmaceutical composition for treating hypertension, diabetes mellitus and cardiovascular diseases

Country Status (8)

Country	Link
US (2)	US20040087630A1 (zh)
EP (1)	EP1359907A2 (zh)
JP (1)	JP2004519424A (zh)
AR (1)	AR030379A1 (zh)
AU (1)	AU2002214952A1 (zh)
PE (1)	PE20020323A1 (zh)
TW (1)	TW200833321A (zh)
WO (1)	WO2002015892A2 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003003971A2 (fr) *	2001-06-20	2003-01-16	Merck Sante	Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant
US20030171407A1 (en) *	2002-03-07	2003-09-11	Upsher-Smith Laboratories, Inc.	Composition for reducing blood glucose and cholesterol
JP2005519949A (ja) *	2002-03-11	2005-07-07	ノバルティスアクチエンゲゼルシャフト	ナテグリニドの塩
TW200810743A (en) *	2002-03-22	2008-03-01	Novartis Ag	Combination of organic compounds
GB0217306D0 (en) *	2002-07-25	2002-09-04	Novartis Ag	Compositions comprising organic compounds
US20070161700A1 (en) *	2004-12-28	2007-07-12	Kowa Company, Ltd.	Inhibitor for the formation of y-secretase complex
US20070254938A1 (en) *	2004-07-01	2007-11-01	Kiyoshi Ichikawa	Preventive or Therapeutic Agent for Vascular Intimal Proliferative Disease
US20100028439A1 (en) *	2005-05-23	2010-02-04	Elan Pharma International Limited	Nanoparticulate stabilized anti-hypertensive compositions
WO2007088705A1 (ja) *	2006-01-31	2007-08-09	Kowa Co., Ltd.	糖尿病治療剤
US8685952B2 (en)	2006-01-31	2014-04-01	Kowa Co., Ltd.	Method for the treatment of diabetes
EP2779999A2 (en)	2011-11-15	2014-09-24	Dr. Reddy's Laboratories Ltd.	Pharmaceutical formulations comprising atorvastatin and glimepiride
US11684567B2 (en)	2015-08-05	2023-06-27	Cmpd Licensing, Llc	Compositions and methods for treating an infection
US12502370B2 (en) *	2019-04-11	2025-12-23	Cmpd Licensing, Llc	Wound treatments and compositions
US11446236B2 (en)	2015-08-05	2022-09-20	Cmpd Licensing, Llc	Topical antimicrobial compositions and methods of formulating the same
US11793783B2 (en)	2015-08-05	2023-10-24	Cmpd Licensing, Llc	Compositions and methods for treating an infection
US12156875B2 (en)	2019-04-11	2024-12-03	Cmpd Licensing, Llc	Wound treatments and compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2275394A1 (en) *	1996-12-23	1998-07-02	Merck & Co., Inc.	Antidiabetic agents
GB0001662D0 (en) *	1999-02-06	2000-03-15	Zeneca Ltd	Pharmaceutical compositions
US6262118B1 (en) *	1999-06-04	2001-07-17	Metabolex, Inc.	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
TWI260321B (en) *	1999-09-22	2006-08-21	Bristol Myers Squibb Co	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
AU2336001A (en) *	1999-12-22	2001-07-03	Merck Frosst Canada & Co.	Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b)
JP2004513076A (ja) *	2000-07-25	2004-04-30	メルク　エンド　カムパニー　インコーポレーテッド	糖尿病治療で有用なｎ−置換インドール類
AU2002251978B2 (en) *	2001-02-09	2007-07-19	Merck & Co., Inc.	2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders

2001
- 2001-08-17 PE PE2001000826A patent/PE20020323A1/es not_active Application Discontinuation
- 2001-08-17 AR ARP010103949A patent/AR030379A1/es unknown
- 2001-08-20 AU AU2002214952A patent/AU2002214952A1/en not_active Abandoned
- 2001-08-20 US US10/362,341 patent/US20040087630A1/en not_active Abandoned
- 2001-08-20 TW TW097116517A patent/TW200833321A/zh unknown
- 2001-08-20 JP JP2002520813A patent/JP2004519424A/ja not_active Withdrawn
- 2001-08-20 EP EP01983442A patent/EP1359907A2/en not_active Withdrawn
- 2001-08-20 WO PCT/EP2001/009586 patent/WO2002015892A2/en not_active Ceased
2008
- 2008-10-27 US US12/290,106 patent/US20090131404A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20040087630A1 (en)	2004-05-06
US20090131404A1 (en)	2009-05-21
AU2002214952A1 (en)	2002-03-04
AR030379A1 (es)	2003-08-20
PE20020323A1 (es)	2002-06-13
WO2002015892A2 (en)	2002-02-28
JP2004519424A (ja)	2004-07-02
EP1359907A2 (en)	2003-11-12
WO2002015892A3 (en)	2003-09-04

Publication	Publication Date	Title
TW200833321A (en)	2008-08-16	Pharmaceutical composition for treating hypertension, diabetes mellitus and cardiovascular diseases
WO2003080070A3 (en)	2004-03-25	Combination comprising an hmg-coa reductase inhibittor and an insulin secretor enhancer or an insulin sensitizer
MXPA04004842A (es)	2004-08-02	Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es)	2004-08-02	Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en)	2004-08-31	Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2001090091A8 (en)	2002-07-25	Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EP2341065A3 (en)	2012-06-20	Inhibitors of serine proteases, particularly HCV NS3-NS4a protease
WO2004033455A3 (en)	2004-05-27	Hemisuccinate salts of heterocyclic dpp-iv inhibitors
YU75903A (sh)	2006-05-25	Tiohidantoini i njihovo korišćenje u lečenju dijabetisa
MXPA02012272A (es)	2003-04-25	Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
CA2504735A1 (en)	2004-05-27	Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO1999040904A3 (en)	1999-09-30	Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the treatment of hyperglycemia
TW200510391A (en)	2005-03-16	Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
UA88270C2 (ru)	2009-10-12	Фармацевтический препарат и его применение для профилактики удара, диабета
MXPA03006364A (es)	2003-10-06	TRATAMIENTO DE PERTURBACIONES DEL SUEnO.
AU2001296865A1 (en)	2002-03-22	(5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
SI1546127T1 (sl)	2008-08-31	Novi pirimidinamidni derivati in njihova uporaba
CA2360451A1 (en)	2000-08-31	N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance
WO2002015933A3 (en)	2003-08-14	Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
WO2002053090A3 (fr)	2003-02-20	Association medicamenteuse d'une biguanine (metformine) et d'arginine
EP1262197A3 (en)	2002-12-18	Combination treatment for sleep disorders including sleep apnea
TW200420304A (en)	2004-10-16	Orally administrable pharmaceutical compositions and methods for preventing food-drug interaction
EP1247533A3 (en)	2003-12-17	Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
BE2016C017I2 (zh)	2021-07-19
MXPA04005033A (es)	2004-08-11	Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.